TG Therapeutics Hits Day High with Strong 7.34% Intraday Surge

TG Therapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 7.34% on August 21, 2026. The stock reached an intraday high of USD 56.84, reflecting a strong day of trading for the small-cap pharmaceutical and biotechnology company. Over the past week, TG Therapeutics has shown impressive growth, with a 1-week performance of 11.35%, significantly outperforming the S&P 500, which declined by 1.43% during the same period. The company's year-to-date performance stands at 82.05%, while its annual growth rate has surged to 88.63%, compared to the S&P 500's 20.47%. Despite these positive trends, the company faces challenges, including a low return on equity of 8.40%, indicating limited profitability relative to shareholder funds. Additionally, the company reported negative results in June 2026 after four consecutive positive quarters, raising concerns about its financial stability. With a market capitalization of USD 5,071 million, TG Therapeutics continues to navigate a complex landscape in the pharmaceuticals and biotechnology sector.